Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 120 clinical trials
None
Ixazomib-pomalidomide-dexamethasone as Second or Third-line Combination Treatment for Patients With Relapsed and Refractory Multiple Myeloma Previously Treated With Daratumumab Lenalidomide and Bortezomib

Adult patients with a confirmed diagnosis of symptomatic and relapsed and/or refractory MM, after receiving bortezomib, lenalidomide and daratumumab during first and second lines, will be

  • 0 views
  • 10 Nov, 2021
  • 7 locations
None
High-Dose Post-Transplant Cyclophosphamide and Bortezomib (CyBor) for the Prevention of Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

This is a single arm open label phase II clinical trial. Adult patients with hematological malignancies undergoing allogeneic HSCT from matched-related or unrelated donor are eligible for the study if they meet the standard criteria defined in the investigator's institutional standard operation procedures (SOPs), meet all inclusion criteria, and do …

allogeneic hematopoietic stem cell transplant
carbon monoxide
bortezomib
cell transplantation
busulfan
  • 1 views
  • 02 May, 2021
  • 1 location
None
Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I

The purpose of this study is to test the good and bad effects of the study drugs bortezomib and vorinostat when they are given in combination with chemotherapy commonly used to treat acute

vorinostat
bortezomib
pegaspargase
lymphoid leukemia
acute leukemia
  • 38 views
  • 13 Nov, 2021
  • 19 locations
None
Comparison of BTD and BCD Based Regimens in the Treatment of AL Amyloidosis

regimens between bortezomib-thalidomide-dexamethasone (BTD) and bortezomib-cyclophosphamide-dexamethasone (BCD) in the treatment of AL amyloidosis, so as to provide more clinical evidence for the standard

electrophoresis
thalidomide
bone marrow procedure
cyclophosphamide
bortezomib
  • 0 views
  • 26 Jan, 2021
  • 1 location
None
A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed Refractory Multiple Myeloma

This is an open-label, single-arm study of ATG-010 (selinexor) plus low-dose Dexamethasone (Sd) in patients with multiple myeloma previously treated with lenalidomide and bortezomib refractory

  • 0 views
  • 27 Jan, 2021
  • 17 locations
None
A Multicentre Non-Blinded Study Exploring Self-Administration of Chemotherapy in the Home Environment

This study is to see if the standard of care subcutaneous injection of bortezomib can safely be administered at home by the patient or caregiver. All tests and assessments are based on standard

bortezomib
chemotherapy regimen
cancer
  • 0 views
  • 02 Jul, 2021
  • 1 location
None
CCCG Relapsed Acute Lymphoblastic Leukemia 2017 Study in Children

lack of efficacy) 2. Adding bortezomid during the induction: The very early or early bone marrow relapse has low remission rate. Previous case studies showed that Bortezomib, a proteasome

  • 0 views
  • 26 Feb, 2021
  • 1 location
None
A Study of Selinexor Plus Low-dose Dexamethasone in Participants With Penta-refractory Multiple Myeloma or Selinexor and Bortezomib Plus Low-dose Dexamethasone in Participants With Triple-class Refractory Multiple Myeloma

or selinexor and bortezomib plus low-dose dexamethasone in participants with triple-class refractory multiple myeloma.

electrophoresis
monoclonal protein
monoclonal antibody therapy
serum protein
bortezomib
  • 0 views
  • 02 Dec, 2021
  • 16 locations
None
VR-CAP in the First-line Treatment for Patients With Marginal Zone Lymphoma

This is a prospective single arm, multi-center, phase II clinical trial to observe the efficacy and safety of VR-CAP (Bortezomib and Rituximab-Cyclophosphamide, Epirubicin and Prednisone) in the

cyclophosphamide
bortezomib
rituximab
prednisone
  • 0 views
  • 23 Aug, 2021
  • 1 location
None
A Study of Daratumumab Carfilzomib Lenalidomide and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma

myeloma than the stand or care treatment, which is lenalidomide, bortezomib, and dexamethasone (VRD).

platelet count
monoclonal protein
bortezomib
serum calcium
growth factor
  • 1 views
  • 05 Dec, 2021
  • 19 locations